April Showers Bring 50 New ICD 10 PCS Codes
As of April 1, 2025, there were 50 new ICD 10-PCS codes added for use through September 30, 2025. The list included OR and non - OR procedures. The additions included, for example, 2 codes for transplantation of the Larynx via an open approach, 2 codes for transfer of the small intestine via open or endoscopic approaches and 6 new codes for resection of the kidney (syngenetic or zooplastic) all via an open approach.
There were 24 additions to the new technology group for Reposition of a bone with “ring external fixation”. Orthopedic external fixators are commonly applied for treating extremity fractures and boney deformities. Patients with an open Gustillo-Anderson grade 3 fracture who had undergone several surgical procedures but still ended up with exposed long dead bone or infected wounds showed great improvement with the Illizarov method (application of a circular fixation device). The Illizarov method has been successfully used to treat long bone and soft tissue defects after repeated debridement and radical resection of dead bone or an infected segment of bone. The efficacy of ilizarov method for management of long tibial bone and soft tissue defect - PMC
Circular fixation devices have been in use for a long time, with the original ring fixation device invented by Illizarov for limb/bone lengthening (distraction osteogenesis). External fixation devices consist of a strut, or a group of struts brought together to construct an extensive frame, which is then connected externally to the bone fragments to stabilize their position. The devices require manual distraction of the struts over time to promote healing. Computer-assisted systems offer a less error-prone treatment alternative to manual fixation by utilizing an attached device and software to plan and implement treatments based on radiological and clinical data. There are multiple systems on the market for this, and each has a little different approach.
The new device allows an automated correction of the struts on the fixator by entering the treatment plan into a device attached to the fixator. The device directs the fixator to make adjustments in sync with the treatment plan. Testing showed the devices to be quite accurate.
https://onlinelibrary.wiley.com/doi/full/10.1002/rcs.2637?msockid=0b3e7e8626636b7c17c96adb27626a38
The new IntelliSep device received FDA 510 (k) clearance on December 19, 2022. The device is indicated for use as an aid to early detection of sepsis in adult patients. Patients with signs and symptoms of infection who present to the Emergency Department are often misdiagnosed as there is no “Classic” presentation of sepsis. This Heterogeneous syndrome has a variety of manifestations and is responsible for the deaths of over a quarter of a million people annually.
According to the minutes of the March 19th Coordination and Maintenance committee for ICD 10 PCS: “The IntelliSep test uses a benchtop instrument designed for the clinical laboratory to assess the state of innate immune activity in under 10 minutes. The instrument evaluates the mechanical properties of white blood cells (leukocytes), which differ in septic patients compared to non-septic patients. According to the requestor, microfluidic cell-handling techniques combined with the technological advances of high-speed imaging and machine learning allow IntelliSep to analyze the biophysical properties of thousands of leukocytes in a few seconds. The results are organized into three interpretation bands, providing guidance to physicians as they triage patients.
A Band 1 result indicates that the patient has a low probability of developing sepsis.
A Band 2 result suggests further investigation may be warranted, allowing for additional assessment.
A Band 3 result indicates a high probability of sepsis and may support the expedited triage of patients.
September-2024-topic-packet-Final.pdf
New Immune Modulators were added as new technology services
September_10_2024__ICD_10_Therapeutic_Agents_Topics.pdf
IMDELLTRA™ (tarlatamab-dlle) is a bispecific DLL3-directed CD3 T-cell engager that binds to DLL3 expressed on the surface of cells, including tumor cells, and CD3 expressed on the surface of T cells. Per the requestor, tarlatamab-dlle causes T-cell activation, release of inflammatory cytokines, and lysis of DLL3-expressing cells. In short this drug allows the body’s own immune system, which was previously suppressed by DLL3 on tumor cells and CDT 3 from T cells, to get back to the business of killing tumor cells.
GAMIFANT™ (emapalumab-lzsg) was granted FDA approval on November 20, 2018, for the treatment of hemophagocytic lymphohistiocytosis (HLH) with primary HLH refractory, recurrent, or progressive disease and intolerance with conventional HLH therapy in adult and pediatric patients. The requestor intends to submit a Supplemental Biologics License Application (sBLA) in the second half of 2024, with a new indication of treatment in adult and pediatric patients with known or suspected secondary hemophagocytic lymphohistiocytosis (sHLH)/macrophage activation syndrome (MAS) in known or suspected Still’s disease (including systemic juvenile idiopathic arthritis [sJIA] and adult-onset Still’s disease [AOSD]) with an inadequate response or intolerance to steroids, or with recurrent MAS.
The full list of ICD 10 PCS code additions can be seen here: web_announcement_icd_10_ms_drgs_v42.1_new_procedure_codes-508.pdf
In this release, there were also 12 deletions from the OSG table all related to fusions of the coccygeal joint.
ELEVATE MEDICAL SOLUTIONS: YOUR TRUSTED PARTNER MEDICAL CODING
At Elevate, we’re dedicated to helping medical coders like you excel. Stay ahead of the curve by subscribing to our blog for the latest resources, industry insights, and exclusive webinars where you can earn AHIMA-approved CEUs—all for free.
Join Our Community Today!